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Introduction: ‘Dropped head sign’ relates to a severe disproportionate antecollis in parkinsonism. We present the
first report of a rotigotine-induced dropped head sign in a patient with suspected idiopathic Parkinson’s disease,
which was later defined as multiple system atrophy. The ‘dropped head sign’ is considered a rare symptom of
unknown etiology in parkinsonian disorders, though a disproportionate antecollis is frequently observed in multiple
system atrophy. It has also been described as a side effect of dopamine agonist medication with cabergoline and
pramipexole. Rotigotine is a transdermally applied, non-ergot dopamine agonist, resulting in a continuous
stimulation of dopamine receptors, which is widely used in the treatment of patients with Parkinson’s disease.
Case presentation: We report a case of a 64-year-old Caucasian woman with a rapidly progressive two-and-a-half-year
history of a hypokinetic Parkinson’s syndrome with asymmetric development of symptoms and an initially good
response to levodopa medication. Due to side effects of other dopamimetic medications the patient was switched to
rotigotine medication five weeks before clinical admission. Progressive antecollis without muscle weakness and
prominent paraspinal muscle contraction developed within two weeks of treatment and resolved within a week after
discontinuation of rotigotine and initiation of levodopa/cabergoline medication.
Conclusion: While the pathophysiology still remains unresolved, this case supports the concept of a dopaminergic
imbalance as a cause of certain axial dystonias like disproportionate antecollis including the ‘dropped head sign’. We
believe this case is specifically useful for neurologists and general practitioners, as the easily recognizable symptom
should prompt a thorough reevaluation of diagnosis and medication in patients with Parkinson’s disease.Introduction
The dropped head sign, also referred to as disproportion-
ate antecollis, describes a pronounced anteflexion of head
and neck in relation to the trunk without relevant weak-
ness of neck muscles, also named dropped head syndrome
by some authors, which usually refers to an isolated weak-
ness of neck extensors [1]. While isolated antecollis is
considered a rare etiology, it has been reported in a variety
of metabolic and neurological conditions [2,3] as well as
neurodegenerative diseases like multiple system atrophy
(MSA) and Parkinson’s disease (PD) [4,5]. The etiology of
disproportionate antecollis in PD is not understood, but it
is considered a form of imbalanced rigidity of neck flexor* Correspondence: christoph.dohm@med.uni-goettingen.de
1Department of Neuroradiology, University Medical Center Göttingen,
Robert-Koch-Str. 40, 37075, Göttingen, Germany
Full list of author information is available at the end of the article
© 2013 Dohm et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orand extensor muscles or a relative weakness of neck ex-
tensor muscles possibly related to neck extensor myop-
athy. Moreover, disproportionate antecollis was described
as a side effect of pramipexole and cabergoline medication
in idiopathic Parkinson’s disease, resolving after discon-
tinuation of dopamine agonist treatment [4,6].
Transdermal application of the dopamine agonist
rotigotine as a once-daily adhesive patch was introduced
into the treatment of PD in Europe in 2006 and became
one of the most prescribed new drugs. In 2008, the pre-
scription rate reached 2.8 million defined daily doses in
Germany, making it the third most prescribed dopamine
agonist following pramipexole and ropinirole [7]. During
the last few years, rotigotine was established as a standard
component in Parkinson’s medication in the early and late
stages of disease. The easy way of application not only of-
fers benefits in terms of medication convenience but alsoLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gastrointestinal side effects. Due to steady-state drug
plasma levels it aims at continuous dopaminergic stimula-
tion. As pulsatile dopaminergic stimulation due to mul-
tiple daily dosing, as seen with levodopa and most oral
medications for PD, is related to motor complications, like
fluctuations and dyskinesias, hopes were raised, that trans-
dermal application would also reduce other motor side ef-
fects in the treatment of PD. Rotigotine is usually well
tolerated; side effects include application site reactions
and other adverse effects known from dopamine agonist
treatment, that is sleepiness, nausea and arrhythmias.
Case presentation
A 64-year-old woman was referred to our department after
she had subacutely developed a progressive disproportion-
ate antecollis five weeks before admission. Parkinson’s dis-
ease had been diagnosed one year before; retrospectively,
she had already noticed slowness of movements for the
previous one and a half years. Nigrostriatal degeneration
was documented by DaTScan™ and, because of asymmetric
development of symptoms and good response to levodopa
medication, a hypokinetic idiopathic Parkinson’s disease
was diagnosed. Despite response to treatment, a satisfac-
tory medication calibration turned out to be difficult and
different medications with ropinirole and entacapone had
to be terminated due to side effects like therapy-resistant
diarrhea and debilitating fatigue. With piribedil medication
the patient had developed prominent leg edema, so
rotigotine up to 8mg per day was added as a substitute to
levodopa, rasagiline and piribedil medication. Within a few
days the patient complained about neck pain, stiffness and
slight antecollis, which did not improve after discontinu-
ation of piribedil medication. Antecollis symptoms sub-
stantially worsened after a further increase of rotigotine
dose to up to 16mg per day, progressing into a dropped
head sign within two weeks after initiation of rotigotine
medication. Clinical deterioration was initially linked to
rasagiline, which was subsequently discontinued without
effect.
Upon clinical presentation the patient showed a pro-
nounced antecollis with severe neck pain. On clinical exam-
ination, an increased activity of head flexor muscles with
prominent contraction of levator scapulae muscles was
found. With effort the head could temporally be lifted off
the chest to some extent, but the patient was able to recline
the head when lying down. Besides, the patient showed a
slightly reduced facial expression with dysarthrophonia, a
right-sided rigor, a slowed gait and a reactive retropulsion of
the upper body to be able to view ahead. Differential diag-
nostic workup of dropped head syndrome, including a mag-
netic resonance imaging (MRI) scan of her head and neck, a
laboratory checkup and examinations for myositis and my-
asthenic syndromes did not reveal pathological findings.Especially, the head MRI scan showed no signs for atypical
Parkinson’s syndrome like putaminal, pontine or cerebellar
atrophy, and midbrain ultrasound revealed a hyperechogenic
substantia nigra on the left side, supporting the diagnosis of
idiopathic PD. Rotigotine dose was reduced and finally
discontinued, resulting in marked improvement of antecollis
within a week. Because of the aggravation of Parkinson’s
symptoms with levodopa monotherapy, a successive
co-medication with cabergoline was started following
cardiologic clearance without relevant side effects even
with doses of up to 6mg per day. Upon external
follow-up the patient reported a slowly progressive re-
currence of antecollis over a few months unrelated to
medication changes, which did not improve after discon-
tinuation of cabergoline medication. MSA was diagnosed
due to the additional development of autonomic dysfunc-
tion and slight ataxia.
Discussion
Disproportionate antecollis is altogether considered a
rare and inconsistent entity; it has been documented in
metabolic and different neurological diseases, including
Parkinson’s syndromes, amyotrophic lateral sclerosis,
myasthenia gravis and Lambert-Eaton’s syndrome, other
forms or myositis and myopathy, facioscapulohumeral
dystrophy, chronic inflammatory demyelinating neur-
opathy, hypokalemic myopathy, hyperparathyroidism and
as side effect of neuroleptic or dopamine agonist treat-
ment. Though dropped head sign seems to be more com-
mon in connection with Parkinson’s syndromes and was
even mentioned in James Parkinson’s famous ‘essay on the
shaking palsy’ [8], epidemiological data on prevalence in
Parkinson’s patients is scarce. Small Japanese cohort inves-
tigations reported a prevalence of up to 6 percent [4,5],
which we would consider an optimistic estimate trans-
ferred to our European patient cohort. This might also re-
late to the descriptive definition of a heterogeneous
symptom.
While the exact etiology of disproportionate antecollis
in parkinsonism is enigmatic, dystonia of neck flexors as
well as weakness of neck extensor muscles or an imbalanced
rigidity of the latter were described [9]. It is noteworthy that,
albeit disproportionate antecollis can indisputably occur in
idiopathic Parkinson’s disease, ‘antecollis’ was reported in
more than half of the pathologically proven cases of multiple
system atrophy and is considered a ‘red flag sign’ for MSA
[10]. Interestingly, Quinn and Fujimoto observed an add-
itional torticollis component in MSA patients [4,10] that
might support clinical differentiation of idiopathic PD from
MSA but it was not found in the presented case. Whether
the patient described in this case report developed a torticol-
lis component at recurrence of antecollis cannot be an-
swered, because follow-up visits were conducted in external
institutions.
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as a special form of other posture abnormalities that one
observes in Parkinson’s patients, like camptocormia (bent
spine syndrome) or pleurothotonus (Pisa syndrome),
referred to as ‘axial dystonias’, which might differ in
the location of specific lesions that cause a dopaminergic-
cholinergic imbalance [11,12]. The dropped head sign has
also been reported as a side effect of neuroleptic medica-
tion [13] and seems to respond better to levodopa therapy
whereas bent spine and Pisa syndrome were not reported
as side effects of dopamine agonist treatment, supporting
the evaluation of dropped head sign as an independent en-
tity in certain cases.
A small number of reports describe the appearance of
dropped head sign caused by ergot and non-ergot dopa-
mine agonist treatment, including cabergoline and
pramipexole. While pathophysiology remains unclear, a
certain similarity of our case to the case reported by
Fujimoto [4] is remarkable; in both cases antecollis due to
increased activity of neck flexor muscles developed sub-
acutely over a few weeks following initiation of treatment
with cabergoline or rotigotine and symptoms resolved
within two weeks after discontinuation of treatment. Con-
sidering that dropped head sign was described following
neuroleptic and dopamine agonist treatment with struc-
turally different agents of ergot and non-ergot back-
bone and relapses under levodopa treatment were not
observed, a pathophysiological concept involving a
dopamine imbalance within the basal ganglia circuit or
a differential sensitivity of muscles to dopamine and
dopamine agonists, as proposed by Horiuchi and col-
leagues [14] is suspected. This view is supported by
our case, where rotigotine medication might have pre-
maturely triggered a disproportionate antecollis in a
predisposed patient with MSA in an early stage of dis-
ease. Nevertheless, we cannot rule out a medication
interaction-induced side effect of rotigotine, that is
with levodopa co-medication.
Furthermore, though different ergot- and non-ergot
dopamine agonists can induce dropped head sign, we
showed that switching to a different dopamine agonist
even at high doses is possible, demonstrating that dis-
position to develop dropped head sign seems to relate to
the specific characteristics of the drug used and not to
the whole group. Because the reappearance of dispropor-
tionate antecollis a few months later did not improve
after discontinuation of cabergoline and marked reduc-
tion of levodopa medication (see Additional file 1), a
medication side effect seems improbable. Prior high-
dose co-medication of levodopa, ropinirole and piribedil
medication did not induce an antecollis (see Additional
file 1 and Additional file 2), suggesting a rotigotine-
specific effect in our patient and not a simple result of
cumulative dopaminergic dosage.Our case further shows, that disproportionate antecollis
related to dopamine agonist treatment is not due to fluc-
tuating drug plasma levels or gastrointestinal drug uptake
and metabolism.
Conclusion
In conclusion, awareness to look for the easily recognizable
dropped head sign in Parkinson’s patients is advised. One
needs to emphasize the highly debilitating nature of this
symptom and the risk of incomplete remission due to
overstretching of neck extensors and osseous remodeling if
recognized too late. Beside the consideration of MSA, the
check-up should include recent medication changes, espe-
cially neuroleptic agents and dopamine agonists. If dopa-
mine agonists turn out to be the suspected culprits, they
should preferably be switched to levodopa therapy. If con-
trol of Parkinson’s symptoms is still insufficient, the
addition of a different dopamine agonist appears feasible.
Transdermal application of rotigotine, though believed to
induce less motor complications than other dopamine ago-
nists, can induce a disproportionate antecollis in certain
patients.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
Additional files
Additional file 1: Retrospective reconstruction of Parkinson’s
disease medication (in mg, DCI – decarboxylase inhibitor) and
dropped head sign/antecollis (arbitrary scale; 10 represents
maximum symptoms), based on clinical examinations, patient’s
descriptions and available medical documentation.
Additional file 2: Extension of Additional file 1 between days 350
and 500. Retrospective reconstruction of Parkinson’s disease medication
(in mg, DCI - decarboxylase inhibitor) and dropped head sign/antecollis
(arbitrary scale; 10 represents maximum symptoms).
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